Trial Profile
Effect of MD1003 in Amyotrophic Lateral Sclerosis: a Randomized Double Blind Placebo Controlled Pilot Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Biotin (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Acronyms MD1003-ALS
- Sponsors MedDay Pharmaceuticals
- 03 Jun 2019 Status changed from active, no longer recruiting to completed.
- 26 Oct 2016 New trial record